SL
Silence Therapeutics plc
SLN · NASDAQ
$14.59 -0.27% (-$0.04)
1M +24.49%
Market Cap $698.6M
P/E Ratio -
Div. Yield -
ROE 106.90%
Piotroski F-Score Weak
1/9Valuation
0 /100
Expensive P/B 18.16x
P/S 1,137.23x
EV/EBITDA N/A
Growth
22 /100
Declining Book val. growth 41.33%
Rev. growth 68.36%
FCF growth N/A
Profitability
20 /100
Weak Net margin 9,755.61%
Op. margin 11,003.00%
FCF margin 6,893.22%
Quality
0 /100
Poor ROE 106.90%
ROA 56.32%
Asset turnover 0.01x
Debt
33 /100
High Current ratio 7.42x
Debt/Equity -0.00x
Net debt/EBITDA N/A
Stability
42 /100
Moderate Rev. volatility 90.95%
EPS volatility 11.98%
Profitable years 0
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o SLN
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Iain Gladstone Ross
Employees
88
Headquarters
London
Prihajajoči dogodki
05 NOV.
Earnings
Upcoming earnings report